March 29, 2018 / 12:29 PM / in 9 months

BRIEF-Insmed Inc Submits NDA To FDA For ALIS

March 29 (Reuters) - Insmed Inc:

* INSMED SUBMITS NEW DRUG APPLICATION TO FDA FOR ALIS IN NTM LUNG DISEASE CAUSED BY MAC

* INSMED - ANTICIPATES RECEIVING A SIX-MONTH PRIORITY REVIEW AND THAT NDA WILL BE REVIEWED BY DIVISION OF ANTI-INFECTIVE PRODUCTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below